Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Indocyanine Green-Guided Manual Lymphatic Drainage for the Prevention of Late-Stage Breast Cancer Related Lymphedema in Breast Cancer Patients Undergoing Axillary Node Dissection

Trial Status: active

This clinical trial compares indocyanine green (ICG)-guided manual lymphatic drainage (MLD) to traditional MLD for the prevention of late-stage breast cancer related lymphedema (BCRL) in breast cancer patients undergoing axillary node dissection. Lymphedema is the build-up of fluid in the body when the lymph system is damaged or blocked. Many breast cancer patients develop BCRL while receiving treatment for their cancer. At the present, there is no cure for this type of lymphedema; however early detection and prevention can prevent progressing to late-stage BCRL. MLD is a type of manual manipulation of the skin that encourages drainage of all regional lymph nodes, which carries fluid away from the tissues back towards the heart. ICG is a dye that helps visualize lymphatic vessels and anatomy using fluorescent light during surgery. In ICG-guided MLD the images of the lymphatic vessels and anatomy captured during surgery are used to help guide MLD focusing on the individual lymphatic pathways. This may be more effective than traditional MLD for the prevention of late-stage BCRL in breast cancer patients undergoing axillary node dissection.